Clinical trial NCT04409392: Staphylococcus Lugdunensis Prosthetic Joint Infection
Official title: Staphylococcus Lugdunensis Prosthetic Joint Infection: a Retrospective Cohort Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Staphylococcal Infections
Prosthetic Joint Infection
Keywords: Staphylococcus lugdunensis
Prosthetic Joint Infection
biofilm
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2020-06-01
Enrollment: 84
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients having had IPA due to Staphylococcus lugdunensis

Brief summary: Staphylococcus lugdunensis is a coagulase-negative staphylococcus belonging to the human commensal cutaneous flora, and has been little studied in the field of prosthetic joint infections. However, it shares many virulence traits with Staphylococcus aureus, including many adhesins and its ability to form biofilm, and the few series of cases reports a significant failure rate.


Eligibility criteria: Inclusion Criteria:

* infection of joint prosthesis (whatever its type) with Staphylococcus lugdunensis defined by the positivity of at least 2 gold-standard samples (joint puncture, intraoperative samples) with S. lugdunensis; OR
* a single positive gold-standard sample or positive blood cultures AND formal clinical, radiological, biological and / or pathological arguments in favor of an infection of joint prosthesis AND absence of other pathogenic agent

Exclusion Criteria:

* none

Primary outcomes:
measure: Rate of PJI infection with Staphylococcus lugdunensis
timeFrame: between 2010 and 2020
measure: Description of PJI infection with Staphylococcus lugdunensis : type
timeFrame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
measure: Description of PJI infection with Staphylococcus lugdunensis : evolution
timeFrame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
measure: Description of patients with PJI infection due to Staphylococcus lugdunensis
timeFrame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
measure: Description of patients with PJI infection due to Staphylococcus lugdunensis : follow up
timeFrame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
measure: Description of patients with PJI infection due to Staphylococcus lugdunensis : medical treatment
timeFrame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
measure: Description of patients with PJI infection due to Staphylococcus lugdunensis : surgical treatment
timeFrame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
measure: rate of treatment failure
timeFrame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
Secondary outcomes:
Other outcomes:
Locations:
city: Lyon
country: France
facility: Hospices Civils de Lyon
Study officials:
References: